financetom
Business
financetom
/
Business
/
Cytokinetics Q2 Loss Narrows, Revenue Declines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cytokinetics Q2 Loss Narrows, Revenue Declines
Aug 8, 2024 2:01 PM

04:34 PM EDT, 08/08/2024 (MT Newswires) -- Cytokinetics ( CYTK ) reported a Q2 loss late Thursday of $1.31 per diluted share, narrower than the loss of $1.34 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.94.

Revenue for the quarter ended June 30 was $249,000, down from $867,000 a year earlier.

Analysts surveyed by Capital IQ expected about $21 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved